**Title of Presentation:** Integrating EDIIA into Cancer Clinical Trials

**Presenter:** Anna Johnson (ajohnson@ctg.queensu.ca)

**Presentation Description:**

Cancer clinical trials should be accessible to all populations affected by the disease and, currently, there are many populations underrepresented in clinical trials including Indigenous peoples, racialized persons, persons with disabilities, women, members of the 2SLGBTQIA+ community, individuals at both ends of the age spectrum, immigrants and refugees, individuals whose primary language is not English or French, and rural and remote populations. Consequently, embedding equity, diversity, inclusivity, indigenization, and accessibility (EDIIA) into cancer clinical trials from trial ideation to result dissemination is imperative for improving health equity and ensuring all individuals have the opportunity for early access to potentially effective treatments. This presentation will provide an overview of strategies for embedding EDIIA into cancer clinical trials and outline several EDIIA initiatives that CCTG will pilot in a prostate trial and a head and neck trial to improve the accessibility of these trials for underrepresented populations.

**Bibliography**

Abdel-Rahman O. Geographic Disparities in Access to Cancer Clinical Trials in Canada. American Journal of Clinical Oncology. 2023. 46(11):512.

Acuña-Villaorduña A, Baranda JC, Boehmer J, Fashoyin-Aje L, Gore SD. Equitable Access to Clinical Trials: How Do We Achieve It? American Society of Clinical Oncology educational book. 2023;43(43):e389838–e389838.

American Society of Clinical Oncology (ASCO). *2022 EDI Blueprint Report.* 2023

Andrasik MP, Broder GB, Wallace SE, Chaturvedi R, Michael NL, Bock S, et al. Increasing Black, Indigenous and People of Color participation in clinical trials through community engagement and recruitment goal establishment. PloS one. 2021;16(10):e0258858–e0258858.

Arring NM, Aduse-Poku L, Jiagge E, Saylor K, White-Perkins D, Israel B, et al. A Scoping Review of Strategies to Increase Black Enrollment and Retention in Cancer Clinical Trials. JCO oncology practice. 2022;18(9):OP2100863-632.

Banda DR, Libin AV, Wang H, Swain SM. A pilot study of a culturally targeted video intervention to increase participation of African American patients in cancer clinical trials. Oncologist. 2012;17(5):708-14. doi: 10.1634/theoncologist.2011-0454. PMID: 22639112; PMCID: PMC3360910.

Food and Drug Administration. Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies. Guidance for Industry. Draft Guidance. June 2024.

Goodson N, Wicks P, Morgan J, Hashem L, Callinan S, Reites J. Opportunities and counterintuitive challenges for decentralized clinical trials to broaden participant inclusion. NPJ digital medicine. 2022;5(1):58–58.

Guerra CE, Fleury ME, Byatt LP, Lian T, Pierce L. Strategies to Advance Equity in Cancer Clinical Trials. American Society of Clinical Oncology educational book. 2022;42(42):1–137.

Kraft SA, Doerr M. Engaging populations underrepresented in research through novel approaches to consent. American journal of medical genetics Part C, Seminars in medical genetics. 2018;178(1):75–80.

López Nancy, Gadsden Vivianl, Editors. Health Inequities, Social Determinants, and Intersectionality. In: National Academy of Medicine; Alexander C, Murry VMB, Bogard K, editors. Perspectives on Health Equity and Social Determinants of Health. Washington (DC): National Academies Press (US); 2017. 1. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK595256/>

Maar MA, Beaudin V, Yeates K, Boesch L, Liu P, Madjedi K, Perkins N, Hua-Stewart D, Beaudin F, Wabano MJ, Tobe SW. Wise Practices for Cultural Safety in Electronic Health Research and Clinical Trials With Indigenous People: Secondary Analysis of a Randomized Clinical Trial. J Med Internet Res. 2019 Nov 4;21(11):e14203. doi: 10.2196/14203. PMID: 31682574; PMCID: PMC6862000.

Mainous AG, Kelliher A, Warne D. Recruiting Indigenous Patients Into Clinical Trials: A Circle of Trust. Annals of family medicine. 2023;21(1):54–6.

National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on the Return of Individual-Specific Research Results Generated in Research Laboratories; Downey AS, Busta ER, Mancher M, et al., editors. Returning Individual Research Results to Participants: Guidance for a New Research Paradigm. Washington (DC): National Academies Press (US); 2018 Jul 10. 5, Advancing Practices for Returning Individual Research Results. Available from: https://www.ncbi.nlm.nih.gov/books/NBK525077/

Nipp RD, Lee H, Powell E, Birrer NE, Poles E, Finkelstein D, et al. Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program. The oncologist (Dayton, Ohio). 2016;21(4):467–74.

Oyer RA, Hurley P, Boehmer L, Bruinooge SS, Levit K, Barrett N, et al. Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. Journal of clinical oncology. 2022;40(19):JCO2200754-2171.

Schroter S, Price A, Malički M, Richards T, Clarke M. Frequency and format of clinical trial results dissemination to patients: a survey of authors of trials indexed in PubMed. BMJ open. 2019;9(10):e032701–e032701.

Shapiro GK, Santiago AT, Pittman T, Iwano K, Rodin G, Cole H, et al. Disparities in clinical trial enrollment at a Canadian comprehensive cancer center: A 15‐year retrospective study. Cancer. 2024;130(16):2782–94.

Versavel S, Subasinghe A, Johnson K, Golonski N, Muhlhausen J, Perry P, et al. Diversity, equity, and inclusion in clinical trials: A practical guide from the perspective of a trial sponsor. Contemporary clinical trials. 2023;126:107092–107092.

Webb D, Stutz S, Hiscock C, Bowra A, Butsang T, Tan S, et al. Indigenous Cultural Safety Trainings for Healthcare Professionals Working in Ontario, Canada: Context and Considerations for Healthcare Institutions. Health Services Insights. 2023;16:11786329231169939–11786329231169939.

**Trials mentioned**

EA1151 / TMIST-- Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer: <https://ecog-acrin.org/clinical-trials/ea1151-tmist-breast-cancer-screening-mammography/>

EAZ171-- Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients with Stage I-III Breast Cancer: https://ecog-acrin.org/clinical-trials/eaz171-breast-cancer/

**Learning Resources**

**Multi-Regional Clinical Trials Centre of Brigham and Women’s Hospital Harvard**- [Diversity, Inclusion, and Equity in Clinical Research](https://mrctcenter.org/diversity-in-clinical-research/)

[Just Ask! Increasing Diversity in Cancer Clinical Research: An ACCC-ASCO Training Program](https://courses.accc-cancer.org/products/just-ask-increasing-diversity-in-cancer-clinical-research#tab-product_tab_overview)

[U.S. FDA Clinical Trial Diversity](https://www.fda.gov/consumers/minority-health-and-health-equity/clinical-trial-diversity)

[3CTN Equity, Diversity, and Inclusion Toolkit](https://3ctn.ca/equity-diversity-and-inclusion-in-clinical-trials/)

[3CTN Improving Trial Access for Indigenous Peoples](https://3ctn.ca/wp-content/uploads/2024/04/Improving-Trial-Access-for-Indigenous-Peoples.pdf)

[Queering Cancer](https://queeringcancer.ca/)

[Ensuring Equitable Access to Cancer Care for Black Patients](https://www.cmaj.ca/content/194/41/E1416)